Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?
US FDA Oncologic Drugs Advisory Committee casts tie vote on proposed expansion of Sutent's renal cell carcinoma indication, mirroring debate FDA having internally.
You may also be interested in...
US FDA’s top cancer drug reviewer has been uncharacteristically quiet during recent advisory committee meetings. That just changed, and the result may not have been great for the sponsor (Pfizer), but it is a reminder of the value that Pazdur’s institutional knowledge and outspokenness bring to all of FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Whether the endpoint can predict overall survival remains unknown, but there is no evidence not to accept it, US FDA advisory committee says.